Transcervical, intrauterine ultrasound-guided radiofrequency ablation of uterine fibroids with the VizAblate? System: three- and six-month endpoint results from the FAST-EU study

详细信息    查看全文

• 作者：Marlies Bongers ; Hans Br?lmann ; Janesh Gupta…
• 关键词：Fibroids ; Radiofrequency ablation ; VizAblate ; Intrauterine sonography
• 刊名：Gynecological Surgery
• 出版年：2015
• 出版时间：February 2015
• 年：2015
• 卷：12
• 期：1
• 页码：61-70
• 全文大小：2,204 KB
• 参考文献：1. Baird, DD, Dunson, DB, Hill, MC (2003) High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 188: pp. 100-107 CrossRef
  2. Dembek, CJ, Pelletier, EM, Isaacson, KB (2007) Payer costs in patients undergoing uterine artery embolization, hysterectomy, or myomectomy for treatment of uterine fibroids. J Vasc Interv Radiol 18: pp. 1207-1213 CrossRef
  3. Manyonda, I, Sinthamoney, E, Belli, AM (2004) Controversies and challenges in the modern management of uterine fibroids. BJOG 111: pp. 95-102 CrossRef
  4. Goldfarb, HA (1992) Avoiding hysterectomy: Nd:YAG laser and bipolar coagulating needle. Clin Laser Mon 10: pp. 191-193
  5. Goldfarb, HA (1995) Bipolar laparoscopic needles for myoma coagulation. J Am Assoc Gynecol Laparosc 2: pp. 175-179 CrossRef
  6. Bergamini, V, Ghezzi, F, Cromi, A (2005) Laparoscopic radiofrequency thermal ablation: a new approach to symptomatic uterine myomas. Am J Obstet Gynecol 192: pp. 768-773 CrossRef
  7. Carrafiello, G, Recaldini, C, Fontana, F (2010) Ultrasound-guided radiofrequency thermal ablation of uterine fibroids: medium-term follow-up. Cardiovasc Intervent Radiol 33: pp. 113-119 CrossRef
  8. Cho, HH, Kim, JH, Kim, MR (2008) Transvaginal radiofrequency thermal ablation: a day-care approach to symptomatic uterine myomas. Aust N Z J Obstet Gynaecol 48: pp. 296-301 CrossRef
  9. Ghezzi, F, Cromi, A, Bergamini, V (2007) Midterm outcome of radiofrequency thermal ablation for symptomatic uterine myomas. Surg Endosc 21: pp. 2081-2085 CrossRef
  10. Jones, S, O’Donovan, P, Toub, D (2012) Radiofrequency ablation for treatment of symptomatic uterine fibroids. Obstet Gynecol Int 2012: pp. 194839
  11. Luo, X, Shen, Y, Song, WX (2007) Pathologic evaluation of uterine leiomyoma treated with radiofrequency ablation. Int J Gynaecol Obstet 99: pp. 9-13 CrossRef
  12. Iversen, H, Lenz, S (2008) Percutaneous ultrasound guided radiofrequency thermal ablation for uterine fibroids: a new gynecological approach. Ultrasound Obstet Gynecol 32: pp. 325 CrossRef
  13. Garza-Leal, JG, Toub, D, León, IH (2011) Transcervical, intrauterine ultrasound-guided radiofrequency ablation of uterine fibroids with the VizAblate System: safety, tolerability, and ablation results in a closed abdomen setting. Gynecol Surg 8: pp. 327-334 CrossRef
  14. Wyatt, KM, Dimmock, PW, Walker, TJ (2001) Determination of total menstrual blood loss. Fertil Steril 76: pp. 125-131 CrossRef
  15. Higham, JM, O’Brien, PM, Shaw, RW (1990) Assessment of menstrual blood loss using a pictorial chart. Br J Obstet Gynaecol 97: pp. 734-739 CrossRef
  16. Warrilow, G, Kirkham, C, Ismail, KMK (2004) Quantification of menstrual blood loss. Obstet Gynaecol 6: pp. 88-92 CrossRef
  17. Spies, JB, Coyne, K, Guaou Guaou, N (2002) The UFS-QOL, a new disease-specific symptom and health-related quality of life questionnaire for leiomyomata. Obstet Gynecol 99: pp. 290-300 CrossRef
  18. Cho, JY, Kim, SH, Kim, SY (2013) Efficacy and safety of daily repeated sonographically guided high-intensity focused ultrasound treatment
• 刊物主题：Gynecology; Minimally Invasive Surgery; Surgical Oncology; Obstetrics/Perinatology; Reproductive Medicine; Interventional Radiology;
• 出版者：Springer Berlin Heidelberg
• ISSN：1613-2084

文摘

This was a prospective, longitudinal, multicenter, single-arm controlled trial, using independent core laboratory validation of MRI results, to establish the effectiveness and confirm the safety of the VizAblate? System in the treatment of symptomatic uterine fibroids. The VizAblate System is a transcervical device that ablates fibroids with radiofrequency energy, guided by a built-in intrauterine ultrasound probe. Fifty consecutive women with symptomatic uterine fibroids received treatment with the VizAblate System. Patients had a minimum Menstrual Pictogram score of 120, no desire for fertility, and met additional inclusion and exclusion criteria. The VizAblate System was inserted transcervically and individual fibroids were ablated with radiofrequency energy. An integrated intrauterine ultrasound probe was used for fibroid imaging and targeting. Anesthesia was at the discretion of each investigator. The primary study endpoint was the percentage change in perfused fibroid volume, as assessed by contrast-enhanced MRI at 3?months. Secondary endpoints, reached at 6?months, included safety, percentage reductions in the Menstrual Pictogram (MP) score and the Symptom Severity Score (SSS) subscale of the Uterine Fibroid Symptom-Quality of Life questionnaire (UFS-QOL), along with the rate of surgical reintervention for abnormal uterine bleeding and the mean number of days to return to normal activity. Additional assessments included the Health-Related Quality of Life (HRQOL) subscale of the UFS-QOL, medical reintervention for abnormal uterine bleeding, and procedure times. Fifty patients were treated, representing 92 fibroids. Perfused fibroid volumes were reduced at 3?months by an average of 68.8?±-7.8?% (P--.0001; Wilcoxon signed-rank test). At 6?months, mean MP and SSS scores decreased by 60.8?±-8.2 and 59.7?±-0.4?%, respectively; the mean HRQOL score increased by 263?±-68?%. There were two serious adverse events (overnight admissions for abdominal pain and bradycardia, respectively) and no surgical reinterventions. These 6-month results suggest that the VizAblate System is safe and effective in providing relief of abnormal uterine bleeding associated with fibroids, with appropriate safety and a low reintervention rate.